A Randomized, Double-blind, Active Control, Parallel Group, Titration, Multicenter Study to Evaluate the Efficacy and Safety of Fimasartan

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 351 participants.

Also called NCT02620306

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 351 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT02620306
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02620306. Randomized; quadruple masking; primary purpose treatment. Start 2016-02-11 (actual); primary completion 2019-12-23 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Randomized, Double-blind, Active Control, Parallel Group, Titration, Multicenter Study to Evaluate the Efficacy and Safety of Fimasartan
Intervention (Drug)
Fimsartan 60mg~120mg
Intervention (Drug)
Fimsartan 60mg~120mg
Intervention (Drug)
Losartan 50mg~100mg
Intervention (Drug)
Losartan 50mg~100mg
Lead sponsor
Boryung Pharmaceutical Co., Ltd (class: industry)

Record details

Record id
cardio:ct-nct02620306
Content hash
58b16b04b9773a8a8c9344a7015205dac779535581f7135f14650ec4b4348efb